BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NeoMatrix Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test


2/2/2010 11:10:16 AM

IRVINE, Calif., Feb. 2 /PRNewswire/ -- NeoMatrix, Inc., developers of the innovative HALO(R) Breast Pap Test, has been awarded a new technology agreement by Novation, the supply contracting company of VHA Inc, University HealthSystem Consortium (UHC) and Provista. This agreement includes the HALO(R) Console, HALO(R) Cart, HALO(R) Patient Interface Cassette and HALO(R) Specimen Collection Cups.

"We are quite proud of being awarded this new technology agreement and look forward to a long-term, mutually beneficial partnership with Novation," said John Stroh, Chief Executive Officer and Director of NeoMatrix. "We consider this contract to be a sign of the dedication of NeoMatrix, Inc., to improving the breast health of women across the country."

About HALO(R)

HALO is designed as a complement to mammography and breast exams, the current standard screening for breast cancer. HALO is not a replacement for current routine screening with breast exams and mammograms. HALO is recommended annually for women over age 25. It is especially helpful for women who are too young for mammograms, or whose mammograms are less effective due to dense breast tissue that can obscure the detection of lesions.

About Novation

Founded in 1998, Novation is the leading health care supply contracting company for more than 2,500 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 14,000 members of Provista, LLC. Novation offers its customers contract development and management, supply chain data and measurement, and industry knowledge and advocacy. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 500 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $35 billion in 2008. For more information on Novation, visit www.novationco.com.

CONTACT: Rebecca Farrell, +1-917-715-7840

Web site: http://www.neomatrix.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES